Cargando…
High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial
BACKGROUND: High-flow nasal cannula (HFNC) oxygen therapy is being increasingly used to prevent post-extubation hypoxemic respiratory failure and reintubation. However, evidence to support the use of HFNC in chronic obstructive pulmonary disease (COPD) patients with hypercapnic respiratory failure a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407427/ https://www.ncbi.nlm.nih.gov/pubmed/32762701 http://dx.doi.org/10.1186/s13054-020-03214-9 |
_version_ | 1783567618190344192 |
---|---|
author | Tan, Dingyu Walline, Joseph Harold Ling, Bingyu Xu, Yan Sun, Jiayan Wang, Bingxia Shan, Xueqin Wang, Yunyun Cao, Peng Zhu, Qingcheng Geng, Ping Xu, Jun |
author_facet | Tan, Dingyu Walline, Joseph Harold Ling, Bingyu Xu, Yan Sun, Jiayan Wang, Bingxia Shan, Xueqin Wang, Yunyun Cao, Peng Zhu, Qingcheng Geng, Ping Xu, Jun |
author_sort | Tan, Dingyu |
collection | PubMed |
description | BACKGROUND: High-flow nasal cannula (HFNC) oxygen therapy is being increasingly used to prevent post-extubation hypoxemic respiratory failure and reintubation. However, evidence to support the use of HFNC in chronic obstructive pulmonary disease (COPD) patients with hypercapnic respiratory failure after extubation is limited. This study was conducted to test if HFNC is non-inferior to non-invasive ventilation (NIV) in preventing post-extubation treatment failure in COPD patients previously intubated for hypercapnic respiratory failure. METHODS: COPD patients with hypercapnic respiratory failure who were already receiving invasive ventilation were randomized to HFNC or NIV at extubation at two large tertiary academic teaching hospitals. The primary endpoint was treatment failure, defined as either resumption of invasive ventilation or switching to the other study treatment modality (NIV for patients in the NFNC group or vice versa). RESULTS: Ninety-six patients were randomly assigned to the HFNC group or NIV group. After secondary exclusion, 44 patients in the HFNC group and 42 patients in the NIV group were included in the analysis. The treatment failure rate in the HFNC group was 22.7% and 28.6% in the NIV group—risk difference of − 5.8% (95% CI, − 23.8–12.4%, p = 0.535), which was significantly lower than the non-inferior margin of 9%. Analysis of the causes of treatment failure showed that treatment intolerance in the HFNC group was significantly lower than that in the NIV group, with a risk difference of − 50.0% (95% CI, − 74.6 to − 12.9%, p = 0.015). One hour after extubation, the mean respiratory rates of both groups were faster than their baseline levels before extubation (p < 0.050). Twenty-four hours after extubation, the respiratory rate of the HFNC group had returned to baseline, but the NIV group was still higher than the baseline. Forty-eight hours after extubation, the respiratory rates of both groups were not significantly different from the baseline. The average number of daily airway care interventions in the NIV group was 7 (5–9.3), which was significantly higher than 6 (4–7) times in the HFNC group (p = 0.006). The comfort score and incidence of nasal and facial skin breakdown of the HFNC group was also significantly better than that of the NIV group [7 (6–8) vs 5 (4–7), P < 0.001] and [0 vs 9.6%, p = 0.027], respectively. CONCLUSION: Among COPD patients with severe hypercapnic respiratory failure who received invasive ventilation, the use of HFNC after extubation did not result in increased rates of treatment failure compared with NIV. HFNC also had better tolerance and comfort than NIV. TRIAL REGISTRATION: chictr.org (ChiCTR1800018530). Registered on 22 September 2018, http://www.chictr.org.cn/usercenter.aspx |
format | Online Article Text |
id | pubmed-7407427 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-74074272020-08-06 High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial Tan, Dingyu Walline, Joseph Harold Ling, Bingyu Xu, Yan Sun, Jiayan Wang, Bingxia Shan, Xueqin Wang, Yunyun Cao, Peng Zhu, Qingcheng Geng, Ping Xu, Jun Crit Care Research BACKGROUND: High-flow nasal cannula (HFNC) oxygen therapy is being increasingly used to prevent post-extubation hypoxemic respiratory failure and reintubation. However, evidence to support the use of HFNC in chronic obstructive pulmonary disease (COPD) patients with hypercapnic respiratory failure after extubation is limited. This study was conducted to test if HFNC is non-inferior to non-invasive ventilation (NIV) in preventing post-extubation treatment failure in COPD patients previously intubated for hypercapnic respiratory failure. METHODS: COPD patients with hypercapnic respiratory failure who were already receiving invasive ventilation were randomized to HFNC or NIV at extubation at two large tertiary academic teaching hospitals. The primary endpoint was treatment failure, defined as either resumption of invasive ventilation or switching to the other study treatment modality (NIV for patients in the NFNC group or vice versa). RESULTS: Ninety-six patients were randomly assigned to the HFNC group or NIV group. After secondary exclusion, 44 patients in the HFNC group and 42 patients in the NIV group were included in the analysis. The treatment failure rate in the HFNC group was 22.7% and 28.6% in the NIV group—risk difference of − 5.8% (95% CI, − 23.8–12.4%, p = 0.535), which was significantly lower than the non-inferior margin of 9%. Analysis of the causes of treatment failure showed that treatment intolerance in the HFNC group was significantly lower than that in the NIV group, with a risk difference of − 50.0% (95% CI, − 74.6 to − 12.9%, p = 0.015). One hour after extubation, the mean respiratory rates of both groups were faster than their baseline levels before extubation (p < 0.050). Twenty-four hours after extubation, the respiratory rate of the HFNC group had returned to baseline, but the NIV group was still higher than the baseline. Forty-eight hours after extubation, the respiratory rates of both groups were not significantly different from the baseline. The average number of daily airway care interventions in the NIV group was 7 (5–9.3), which was significantly higher than 6 (4–7) times in the HFNC group (p = 0.006). The comfort score and incidence of nasal and facial skin breakdown of the HFNC group was also significantly better than that of the NIV group [7 (6–8) vs 5 (4–7), P < 0.001] and [0 vs 9.6%, p = 0.027], respectively. CONCLUSION: Among COPD patients with severe hypercapnic respiratory failure who received invasive ventilation, the use of HFNC after extubation did not result in increased rates of treatment failure compared with NIV. HFNC also had better tolerance and comfort than NIV. TRIAL REGISTRATION: chictr.org (ChiCTR1800018530). Registered on 22 September 2018, http://www.chictr.org.cn/usercenter.aspx BioMed Central 2020-08-06 /pmc/articles/PMC7407427/ /pubmed/32762701 http://dx.doi.org/10.1186/s13054-020-03214-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Tan, Dingyu Walline, Joseph Harold Ling, Bingyu Xu, Yan Sun, Jiayan Wang, Bingxia Shan, Xueqin Wang, Yunyun Cao, Peng Zhu, Qingcheng Geng, Ping Xu, Jun High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial |
title | High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial |
title_full | High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial |
title_fullStr | High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial |
title_full_unstemmed | High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial |
title_short | High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial |
title_sort | high-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407427/ https://www.ncbi.nlm.nih.gov/pubmed/32762701 http://dx.doi.org/10.1186/s13054-020-03214-9 |
work_keys_str_mv | AT tandingyu highflownasalcannulaoxygentherapyversusnoninvasiveventilationforchronicobstructivepulmonarydiseasepatientsafterextubationamulticenterrandomizedcontrolledtrial AT wallinejosephharold highflownasalcannulaoxygentherapyversusnoninvasiveventilationforchronicobstructivepulmonarydiseasepatientsafterextubationamulticenterrandomizedcontrolledtrial AT lingbingyu highflownasalcannulaoxygentherapyversusnoninvasiveventilationforchronicobstructivepulmonarydiseasepatientsafterextubationamulticenterrandomizedcontrolledtrial AT xuyan highflownasalcannulaoxygentherapyversusnoninvasiveventilationforchronicobstructivepulmonarydiseasepatientsafterextubationamulticenterrandomizedcontrolledtrial AT sunjiayan highflownasalcannulaoxygentherapyversusnoninvasiveventilationforchronicobstructivepulmonarydiseasepatientsafterextubationamulticenterrandomizedcontrolledtrial AT wangbingxia highflownasalcannulaoxygentherapyversusnoninvasiveventilationforchronicobstructivepulmonarydiseasepatientsafterextubationamulticenterrandomizedcontrolledtrial AT shanxueqin highflownasalcannulaoxygentherapyversusnoninvasiveventilationforchronicobstructivepulmonarydiseasepatientsafterextubationamulticenterrandomizedcontrolledtrial AT wangyunyun highflownasalcannulaoxygentherapyversusnoninvasiveventilationforchronicobstructivepulmonarydiseasepatientsafterextubationamulticenterrandomizedcontrolledtrial AT caopeng highflownasalcannulaoxygentherapyversusnoninvasiveventilationforchronicobstructivepulmonarydiseasepatientsafterextubationamulticenterrandomizedcontrolledtrial AT zhuqingcheng highflownasalcannulaoxygentherapyversusnoninvasiveventilationforchronicobstructivepulmonarydiseasepatientsafterextubationamulticenterrandomizedcontrolledtrial AT gengping highflownasalcannulaoxygentherapyversusnoninvasiveventilationforchronicobstructivepulmonarydiseasepatientsafterextubationamulticenterrandomizedcontrolledtrial AT xujun highflownasalcannulaoxygentherapyversusnoninvasiveventilationforchronicobstructivepulmonarydiseasepatientsafterextubationamulticenterrandomizedcontrolledtrial |